ABBOTT LABORATORIES Accumulated Other Comprehensive Income
ABBOTT LABORATORIES (ABT) had Accumulated Other Comprehensive Income of -$6.31 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-04-29
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.31B.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.00B.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.68B.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.58B.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-03-31 | -$6.31B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | -$6.00B 10-Q · filed 2026-04-29 | |
| 2025-09-30 | -$6.68B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | -$6.58B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | -$7.42B 10-Q · filed 2025-04-30 | |
| 2024-12-31 | -$7.91B 10-K · filed 2026-02-20 | |
| 2024-09-30 | -$7.80B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$8.13B 10-Q · filed 2024-07-31 | |
| 2024-03-31 | -$8.17B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$7.84B 10-K · filed 2026-02-20 | |
| 2023-09-30 | -$8.48B 10-Q · filed 2023-11-01 | |
| 2023-06-30 | -$8.07B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$8.04B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$8.05B 10-K · filed 2025-02-21 | |
| 2022-09-30 | -$9.45B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | -$8.71B 10-Q · filed 2022-08-02 | |
| 2022-03-31 | -$8.47B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | -$8.37B 10-K · filed 2024-02-16 | |
| 2021-09-30 | -$9.24B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$9.07B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | -$9.29B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | -$8.95B 10-K · filed 2023-02-17 | |
| 2020-09-30 | -$9.04B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | -$9.08B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | -$9.39B 10-Q · filed 2020-04-29 | |
| 2019-12-31 | -$8.46B 10-K · filed 2022-02-18 | |
| 2019-09-30 | -$7.76B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | -$7.37B 10-Q · filed 2019-07-31 | |
| 2019-03-31 | -$7.47B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | -$7.59B 10-K · filed 2021-02-19 | |
| 2018-09-30 | -$7.01B 10-Q · filed 2018-10-31 | |
| 2018-06-30 | -$6.91B 10-Q · filed 2018-08-01 | |
| 2018-03-31 | -$5.73B 10-Q · filed 2018-05-02 | |
| 2017-12-31 | -$6.06B 10-K · filed 2020-02-21 | |
| 2017-09-30 | -$6.12B 10-Q · filed 2017-11-02 | |
| 2017-06-30 | -$6.25B 10-Q · filed 2017-08-02 | |
| 2017-03-31 | -$6.53B 10-Q · filed 2017-05-03 | |
| 2016-12-31 | -$7.26B 10-K · filed 2019-02-22 | |
| 2016-09-30 | -$6.53B 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$7.22B 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$6.85B 10-Q · filed 2016-05-04 | |
| 2015-12-31 | -$6.66B 10-K · filed 2018-02-16 | |
| 2015-09-30 | -$7.21B 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$5.00B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | -$5.61B 10-Q · filed 2015-05-06 | |
| 2014-12-31 | -$5.05B 10-K · filed 2016-02-19 | |
| 2014-09-30 | -$2.98B 10-Q · filed 2014-11-06 | |
| 2014-06-30 | -$1.95B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | -$1.93B 10-Q · filed 2014-05-07 | |
| 2013-12-31 | -$2.01B 10-K · filed 2015-02-27 | |
| 2013-09-30 | -$2.96B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | -$3.23B 10-Q · filed 2013-08-06 | |
| 2013-03-31 | -$2.89B 10-Q · filed 2013-05-08 | |
| 2012-12-31 | -$3.59B 10-K · filed 2015-02-27 | -$3.59B 10-K · filed 2013-02-15 |
| 2012-09-30 | -$2.76B 10-Q · filed 2012-11-07 | |
| 2012-06-30 | -$3.54B 10-Q · filed 2012-08-07 | |
| 2012-03-31 | -$1.94B 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $212.00M 10-K · filed 2014-02-21 | -$2.60B 10-K · filed 2012-02-21 |
| 2011-09-30 | -$860.28M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $577.78M 10-Q · filed 2011-08-04 | |
| 2011-03-31 | $182.05M 10-Q · filed 2011-05-06 | |
| 2010-12-31 | -$1.37B 10-K · filed 2014-02-21 | -$1.37B 10-K · filed 2011-02-18 |
| 2010-09-30 | -$1.48B 10-Q · filed 2010-11-05 | |
| 2010-06-30 | -$2.63B 10-Q · filed 2010-08-05 | |
| 2010-03-31 | -$975.67M 10-Q · filed 2010-05-04 | |
| 2009-12-31 | $854.07M 10-K · filed 2012-02-21 | |
| 2009-09-30 | $498.97M 10-Q · filed 2009-11-06 | |
| 2009-06-30 | -$6.62M 10-Q · filed 2009-08-07 | |
| 2008-12-31 | -$1.16B 10-K · filed 2011-02-18 | |
| 2007-12-31 | $2.08B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |